( Demonstrates Positive Effect on Objecti...)Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo,Health

MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- According to study results presented today at SLEEP 2007, the 21st annual meeting of the Associated Professional Sleep Societies (APSS), VEC-162, a balanced melatonin (MT1/MT2) receptor agonist being developed by Vanda Pharmaceuticals Inc. , demonstrated improvements in objective and subjective measures of sleep onset and maintenance in a Phase III trial of transient insomnia.

VEC-162 was assessed in a randomized, double-blind, placebo-controlled, multi-center clinical trial that enrolled 412 adults in a sleep laboratory setting using a phase-advance, first-night assessment model of transient insomnia. The trial examined VEC-162 dosed 30 minutes before bedtime at 20, 50 and 100 mg versus placebo.

"Study patients reported they were falling asleep faster and staying asleep longer," said Tom Roth, Ph.D., Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, presenter at today's APSS session. "These subjective measures support data collected in the sleep lab and provide an important dimension for assessing the efficacy of VEC-162."

VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo (p<0.001) in the primary endpoint of the trial, Latency to Persistent Sleep (LPS), a measure of sleep onset. VEC-162 also produced statistically significant improvements relative to placebo in Latency to Non-Awake (LNA), another measure of sleep onset, Wake After Sleep Onset (WASO), a measure of sleep maintenance, and Total Sleep Time (TST). VEC-162 was also demonstrated to be safe and well tolerated.

VEC-162 also demonstrated improvements relative to placebo on subjective sleep measures. For LPS, all VEC-162 doses showed a trend toward improvement and 50 mg (p<0.001) and 100 mg (p=0.018) achieved statistical
'"/>